Prevalence of Non-Alcoholic Fatty Liver Disease in Women With Polycystic Ovary Syndrome and Its Correlation With Metabolic Syndrome

Romanowski, Mariana Drechmer; Parolin, Mônica Beatriz; Freitas, Alexandre Coutinho Teixeira de; Piazza, Mauri José; Basso, Jorgete; Urbanetz, Almir Antônio

doi:10.1590/s0004-28032015000200008

Cited by 44 publications

(38 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the relationship between older age and increased prevalence of NAFLD is confirmed in female subjects from the NHANES . However, among the female population, various other factors, including alterations in body composition, fat distribution, hormonal and metabolic changes after menopause, as well as polycystic ovary disease, have been associated with NAFLD . In fact, data suggest that estrogen appears to have a protective role.…”

Section: Discussionsupporting

confidence: 93%

Prevalence of Nonalcoholic Fatty Liver Disease in the Female Population

et al. 2018

View full text Add to dashboard Cite

There is a paucity of recent data about the epidemiology and long‐term outcomes of nonalcoholic fatty liver disease (NAFLD) in the female population. Our aim was to assess the prevalence, risk factors, and mortality of NAFLD in female adults of the United States. Data from the National Health and Nutrition Examination Survey (NHANES) III and NHANES 1999‐2014 were used. NAFLD status was determined by the U.S. Fatty Liver Index (US‐FLI) in the absence of other liver diseases and excessive alcohol consumption. The prevalence rates, risk factors, and 5‐year all‐cause and cardiovascular mortality were determined in women with NAFLD. The most recent prevalence of NAFLD among female adults (2007‐2014) in the United States was 24.4% (95% confidence interval [CI], 22.48‐26.33). Prevalence was higher among women >44 years of age and those with body mass index ≥30 kg/m2. In addition, the average age of the female population with NAFLD has decreased over time. The fully adjusted odds ratios in women with NAFLD compared to those without NAFLD were 1.48 (95% CI, 1.20‐1.82) for cardiovascular disease (CVD), 1.89 (95% CI, 1.42‐2.52) for atherosclerotic cardiovascular disease (ASCVD) score ≥7.5%, and 1.76 (95% CI, 1.37‐2.25) for either CVD or ASCVD ≥7.5%. The 5‐year mortality for female adults with NAFLD was significantly higher than for those without NAFLD (adjusted hazard ratio, 1.48; 95% CI, 1.07‐2.05). Among women with NAFLD, those with ASCVD ≥7.5% had significantly higher 5‐year all‐cause mortality and CVD mortality. Conclusion: The prevalence of NAFLD in female NHANES participants from the United States has continued over recent years. In the female population with NAFLD, ASCVD ≥7.5% is an independent predictor of overall and cardiac‐specific mortality.

show abstract

Section: Discussionsupporting

confidence: 93%

Prevalence of Nonalcoholic Fatty Liver Disease in the Female Population

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Metabolic syndrome for adults was defined by different criteria, for example 25 articles used the Adult Treatment Panel III (ATP III) and its modifications criteria . Six articles used the American Heart Association/National Heart Lung Blood Institute (AHA) and its modification criteria .…”

Section: Resultsmentioning

confidence: 99%

“…Table presents the assessment of method quality, according to the Newcastle‐Ottawa Scale. Eleven articles achieved scores of seven or more of nine indicating high quality, and six articles achieved score of 5 indicating low quality …”

Section: Resultsmentioning

confidence: 99%

The risk of metabolic syndrome in polycystic ovary syndrome: A systematic review and meta‐analysis

Behboudi‐Gandevani

Amiri

Yarandi

et al. 2017

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

“…Insulin and luteinizing hormone act synergistically, stimulating ovarian theca cells to increase androgen synthesis, inhibiting synthesis of the steroid hormone binding globulin by the liver and increasing the amount of free and biologically active testosterone in circulation. Because IR is the characteristic of MetS, several reports have shown that women with PCOS are more likely to have MetS c[169-171]. Other studies have shown that women with PCOS, regardless of their body weight, have a higher risk for the development of NAFLD.…”

Section: Nonalcoholic Fatty Liver Disease Polycycstic Ovarian Syndromentioning

confidence: 99%

“…Published studies of the coherence between PCOS and NAFLD are still very rare. Further studies are needed to confirm the relationships between these conditions[4,169]. …”

Section: Nonalcoholic Fatty Liver Disease Polycycstic Ovarian Syndromentioning

confidence: 99%

Nonalcoholic fatty liver disease - A multisystem disease?

Mikolašević

Milić

Wensveen

et al. 2016

WJG

146

148

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is one of the most common comorbidities associated with overweight and metabolic syndrome (MetS). Importantly, NAFLD is one of its most dangerous complications because it can lead to severe liver pathologies, including fibrosis, cirrhosis and hepatic cellular carcinoma. Given the increasing worldwide prevalence of obesity, NAFLD has become the most common cause of chronic liver disease and therefore is a major global health problem. Currently, NAFLD is predominantly regarded as a hepatic manifestation of MetS. However, accumulating evidence indicates that the effects of NAFLD extend beyond the liver and are negatively associated with a range of chronic diseases, most notably cardiovascular disease (CVD), diabetes mellitus type 2 (T2DM) and chronic kidney disease (CKD). It is becoming increasingly clear that these diseases are the result of the same underlying pathophysiological processes associated with MetS, such as insulin resistance, chronic systemic inflammation and dyslipidemia. As a result, they have been shown to be independent reciprocal risk factors. In addition, recent data have shown that NAFLD actively contributes to aggravation of the pathophysiology of CVD, T2DM, and CKD, as well as several other pathologies. Thus, NAFLD is a direct cause of many chronic diseases associated with MetS, and better detection and treatment of fatty liver disease is therefore urgently needed. As non-invasive screening methods for liver disease become increasingly available, detection and treatment of NAFLD in patients with MetS should therefore be considered by both (sub-) specialists and primary care physicians.

show abstract

Prevalence of Non-Alcoholic Fatty Liver Disease in Women With Polycystic Ovary Syndrome and Its Correlation With Metabolic Syndrome

Cited by 44 publications

References 27 publications

Prevalence of Nonalcoholic Fatty Liver Disease in the Female Population

Prevalence of Nonalcoholic Fatty Liver Disease in the Female Population

The risk of metabolic syndrome in polycystic ovary syndrome: A systematic review and meta‐analysis

Nonalcoholic fatty liver disease - A multisystem disease?

Contact Info

Product

Resources

About